| Literature DB >> 35439114 |
Tiantian Wei1,2,3, Jue Wang4, Ruqi Liang1,2,4, Wendong Chen5, Yilan Chen6, Mingzhe Ma4, An He7, Yifei Du4, Wenjing Zhou8, Zhiying Zhang1, Xin Zeng1,4, Chu Wang1,4, Jin Lu9,10, Xing Guo11, Xiao-Wei Chen1,8, Youjun Wang6, Ruijun Tian5,6, Junyu Xiao1,2,3,12, Xiaoguang Lei1,2,4,13.
Abstract
The dual-specificity tyrosine phosphorylation-regulated kinase DYRK2 has emerged as a critical regulator of cellular processes. We took a chemical biology approach to gain further insights into its function. We developed C17, a potent small-molecule DYRK2 inhibitor, through multiple rounds of structure-based optimization guided by several co-crystallized structures. C17 displayed an effect on DYRK2 at a single-digit nanomolar IC50 and showed outstanding selectivity for the human kinome containing 467 other human kinases. Using C17 as a chemical probe, we further performed quantitative phosphoproteomic assays and identified several novel DYRK2 targets, including eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) and stromal interaction molecule 1 (STIM1). DYRK2 phosphorylated 4E-BP1 at multiple sites, and the combined treatment of C17 with AKT and MEK inhibitors showed synergistic 4E-BP1 phosphorylation suppression. The phosphorylation of STIM1 by DYRK2 substantially increased the interaction of STIM1 with the ORAI1 channel, and C17 impeded the store-operated calcium entry process. These studies collectively further expand our understanding of DYRK2 and provide a valuable tool to pinpoint its biological function.Entities:
Keywords: biochemistry; cancer; chemical biology; dyrk2, kinase inhibitor, quantitative phosphoproteomics,4e-binding protein 1, stromal interaction molecule 1; kinase; protein synthesis
Mesh:
Substances:
Year: 2022 PMID: 35439114 PMCID: PMC9113749 DOI: 10.7554/eLife.77696
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.713